Prothena Corporation plc Logo

Email this page: News Release

Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis

For security reasons, registration is required before you can use this feature.
* Indicates required field